Related Experiment Video
Updated: Jul 21, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.8K
Pharmacokinetic Interaction between Imatinib and Tacrolimus in Rats
Naling Fan1, Teng Guo1, Liying Du1
1Department of Pharmacy, the Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, China.
Current Drug Metabolism
|December 24, 2024
Summary
Imatinib significantly increased tacrolimus levels in rats, while tacrolimus reduced imatinib concentrations after multiple doses. This indicates potential drug-drug interactions when co-administering these medications.
Area of Science:
- Pharmacology
- Drug Metabolism
- Drug Interactions
Background:
- Tacrolimus is a calcineurin inhibitor (CNI) used for chronic myeloid leukemia (CML) and advanced gastrointestinal stromal tumors (GIST).
- Imatinib and tacrolimus are metabolized by CYP3A4/5 and transported by P-gp, suggesting potential drug-drug interactions (DDIs).
Purpose of the Study:
- To evaluate the pharmacokinetic interaction between imatinib and tacrolimus in a rat model.
- To assess the impact of co-administration on the concentrations of both drugs.
Main Methods:
- Rats were administered varying doses of imatinib and/or tacrolimus for 14 days.
- Whole blood tacrolimus and plasma imatinib (including N-desmethyl imatinib) concentrations were measured using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS).
Main Results:
- Single-dose imatinib did not significantly affect tacrolimus pharmacokinetics, but imatinib increased tacrolimus AUC and Cmax.
- Multiple-dose tacrolimus significantly reduced imatinib and N-desmethyl imatinib AUC and Cmax.
- Imatinib significantly increased tacrolimus AUC0-24 and AUC0-∞ after multiple doses.
Conclusions:
- Imatinib increases tacrolimus blood concentrations following both single and multiple administrations.
- Tacrolimus may affect imatinib absorption and metabolism after multiple doses, necessitating caution during co-administration.
- Clinicians should monitor for drug-drug interactions when prescribing imatinib and tacrolimus concurrently.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...